European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy for the Treatment…
Gilead Sciences, Inc. announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...
Read More...
